Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:

Galectin Therapeutic (GALT)

Galectin Therapeutic (GALT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Galectin Therapeutics Announces Acceptance of Three Abstracts for the American Association for the Study of Liver Diseases (AASLD) 2024 Liver Meeting GlobeNewswire - Tue Oct 15, 7:00AM CDT

GALT : 2.96 (+2.42%)
Options - shutterstock_170780711
Rating the Top 4 Unusually Active Call Options From Thursday’s Trading Barchart - Fri Apr 12, 12:00PM CDT

The top four unusually active call options in Thursday trading had an average Vol/OI ratio of 52.25. While that’s not very high, each has compelling reasons to buy. Here's why.

JPM : 239.56 (+0.11%)
FTDR : 56.78 (-1.70%)
GALT : 2.96 (+2.42%)
KKR : 153.16 (-1.76%)
CPRI : 19.39 (-2.76%)
TPR : 51.17 (-0.68%)
Madrigal Pharmaceuticals Wins Approval for the First Drug Targeting the Multibillion-Dollar NASH Market. Is the Stock a Screaming Buy? Motley Fool - Sun Mar 17, 4:50AM CDT

Madrigal's Rezdiffra will have the NASH market all to itself -- at least for a while.

GALT : 2.96 (+2.42%)
GLMD : 3.02 (+4.86%)
VKTX : 60.60 (-3.76%)
ETNB : 9.05 (-9.95%)
IVA : 2.64 (-2.22%)
SGMT : 5.94 (+1.54%)
TERN : 7.17 (-3.89%)
NVO : 107.06 (-1.86%)
IQV : 213.57 (-1.58%)
MDGL : 339.04 (-0.18%)
Galectin Therapeutics Announces $60 Million Credit Line from Richard E. Uihlein Sufficient to Cover Expected Expenditures Through 2024 Globe Newswire - Tue Jul 26, 2022

NORCROSS, Ga., July 26, 2022 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin...

GALT : 2.96 (+2.42%)
Galectin Therapeutics Announces 2 Liver Cirrhosis Scientific Presentations at the EASL International Liver Congress™ 2022 Globe Newswire - Tue Jun 21, 2022

NORCROSS, Ga., June 21, 2022 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin-3,...

GALT : 2.96 (+2.42%)
Galectin Therapeutics to Present in Upcoming H.C. Wainwright Global Investment Conference and the 5th Global NASH Congress Globe Newswire - Mon May 23, 2022

NORCROSS, Ga., May 23, 2022 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin...

GALT : 2.96 (+2.42%)
Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2022 and Provides Business Update Globe Newswire - Mon May 16, 2022

NORCROSS, Ga., May 16, 2022 (GLOBE NEWSWIRE) --  Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin...

GALT : 2.96 (+2.42%)
Galectin Therapeutics Reports 2021 Financial Results and Provides Business Update Globe Newswire - Thu Mar 31, 2022

NORCROSS, Ga., March 31, 2022 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin...

GALT : 2.96 (+2.42%)
Galectin Therapeutics to Present at the H.C. Wainwright BioConnect Conference Globe Newswire - Thu Jan 6, 2022

NORCROSS, Ga., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin...

GALT : 2.96 (+2.42%)
Galectin Therapeutics Announces Closing of $10 Million in Debt Financing from Its Chairman, Richard E. Uihlein Globe Newswire - Tue Dec 21, 2021

NORCROSS, Ga., Dec. 21, 2021 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin...

GALT : 2.96 (+2.42%)

Barchart Exclusives

1 Dividend Aristocrat to Bet on Trump's Tariffs and the Fed's Rate Cuts Barchart - 30 minutes ago
Nucor is one stock that stands to benefit from the Fed's rate cuts as well as any possible tariffs under a Trump administration. It is also a dividend aristocrat, and has increased its payouts for over 5 decades. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot